dTACE-HAIC Combined With Bevacizumab and Atezolizumab for Huge Hepatocellular Carcinoma

NARecruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

October 1, 2024

Primary Completion Date

October 1, 2025

Study Completion Date

June 30, 2026

Conditions
Advanced Hepatocellular CarcinomaAtezolizumabBevacizumabChemotherapy
Interventions
PROCEDURE

dTACE-HAIC

dTACE procedure was a 2.8-F microcatheter was super-selectively inserted into the tumor feeding artery using the coaxial technique. Then drug-eluting microspheres were used (100-300um). The microcatheter was reserved at the proper/left/right hepatic artery according tumor location. After the patient returned to the ward, the following FOLFOX-based regime was intra-arterially administered through the microcatheter. The FOLFOX regimen was administered via the hepatic artery as follows: 85 or 135 mg/m2 oxaliplatin from hour 0 to 2 on day 1, and 400 mg/m2 leucovorin from hour 2 to 4 on day 1, and 400 mg/m2 fluorouracil bolus at hour 5 on the day 1; and 2400 mg/m2 fluorouracil over 46 h on days 1 and 2. Hepatic arterial infusion chemotherapy administration of oxaliplatin, fluorouracil, and leucovorin via the tumor feeding arteries every 4 weeks

Trial Locations (1)

100853

RECRUITING

Chinese PLA General hospital, Beijing

All Listed Sponsors
lead

Sun Yat-sen University

OTHER